Having successfully developed hotspot regulatory binders at other biotechnology companies, our co-founders recognized the opportunity to advance this modality by designing a purposeful and systematic approach to finding and targeting regulatory hotspots. We’ve assembled an incredible team of scientists and industry experts with a strong track record of bringing new thinking to complex drug discovery challenges.

Management

Jonathan Montagu
Jonathan Montagu
Co-Founder and Chief Executive Officer
Biography
Geraldine Harriman
Geraldine Harriman, PhD
Co-Founder and Chief Scientific Officer
Biography
eva jack
Eva Jack
Chief Operating Officer
Biography
Tim Reilly
Tim Reilly, PhD
Chief Development Officer
Biography
paul thibodeau
Paul Thibodeau, PhD
Chief Business Officer
Biography
Jonathan Montagu
Jonathan Montagu
Co-Founder and Chief Executive Officer

A trained chemist, biotech entrepreneur and specialist in startup operations and business development, Jonathan’s unique perspective aligns business and science interests. Inspired by the ability to translate lab-bench innovation into meaningful therapies for patients, Jonathan is driven to lead HotSpot to solve problems that the industry has grappled with for decades.

Prior to co-founding HotSpot, Jonathan served as Chief Business Officer at Nimbus Therapeutics, where he helped establish the company’s drug discovery platform and pipeline. He also served as Vice President, Business Development at Concert Pharmaceuticals (CNCE), and was instrumental in securing a $1B multi-product transaction for the company with GSK. Jonathan serves as a Non-Executive Director at OMass Therapeutics and is currently an Advisor at Atlas Venture.

Jonathan trained as a chemist at Oxford University, Cold Spring Harbor Laboratory, The Scripps Research Institute, and Cancer Research UK.  Jonathan received an MBA from Stanford Graduate School of Business.

Geraldine Harriman
Geraldine Harriman, PhD
Co-Founder and Chief Scientific Officer

Working for more than 20 years in drug discovery & early development, Gerry’s strong experience allows her to move seamlessly from one area of science to another, guiding cross-disciplinary problem solving. Drawn to medicine at an early age, she was fascinated to learn how the body works at its most basic level. This, together with her love of innovation, chemistry and biology culminated into a desire to discover new medicines.

Prior to co-founding HotSpot, Gerry served as Vice President and Head of ACC Program at Nimbus Therapeutics, where she led the effort to discover a leading drug for NASH. She also served as Vice President at Galenea, co-led the Inflammation Therapeutic Area at Millennium Pharmaceuticals, and was a founding member of the scientific team at LeukoSite.

Gerry received her Ph.D. in Chemistry at the University of Rhode Island and completed her post-doc fellowship at The University of Kansas.

eva jack
Eva Jack
Chief Operating Officer

Ms. Jack, a proven leader in the biopharmaceutical industry, brings a broad scope of business and operational experience to HotSpot Therapeutics. She has a highly successful track record in leading financings, forming and negotiating strategic collaborations, facilitating strategy development, and building and leading business, finance and other administrative functions.

She joins the team from Mersana Therapeutics, where she was the Chief Business Officer and played a major role in transforming the company from an early-stage start-up to a publicly traded, clinical-stage organization. She has also consulted with biotech companies and investors on business and financing strategies. Previously, she served as the Chief Business Officer of Pulmatrix, and before that, she was with MedImmune (acquired by AstraZeneca). While at MedImmune Ms. Jack was Managing Director of MedImmune Ventures, where she was responsible for making and managing investments in private biotechnology companies. Prior to MedImmune Ventures, she was in MedImmune’s Business Development group, where she was responsible for in-licensing, out-licensing and research collaborations. Prior to joining MedImmune, Ms. Jack held a variety of positions at Intel Corporation, where she worked in venture investments, corporate strategy and public policy.

Ms. Jack holds a bachelor’s degree from the University of Virginia and a master’s degree in health sciences from The Johns Hopkins University.  Additionally, she is a volunteer puppy raiser for Canine Companions for Independence®, a non-profit organization that enhances the lives of people with disabilities by providing highly trained assistance dogs.

Tim Reilly
Tim Reilly, PhD
Chief Development Officer

Dr. Reilly has extensive expertise in drug development across a range of therapeutic modalities and disease areas, with a proven track record of success in pharmaceutical R&D. Currently, he leads HotSpot’s drug development efforts focused on the strategy and operational components of bringing our new molecules into clinical development.

He joins HotSpot from Bristol Myers Squibb, where he held positions of increasing leadership responsibility during his 18-year tenure. Most recently he was Senior Vice President, Early Development Program Leadership, where he oversaw the entire early development portfolio spanning multiple modalities and therapeutic areas and established the overall strategic and operational plans from development candidate identification through Phase 1 and Phase 2 clinical development. He has made significant contributions to well over 150 clinical stage molecules during the course of his career.

Dr. Reilly is the industry representative to the Network Steering Committee of the Experimental Cancer Medicines Centres (ECMC) established by Cancer Research UK, is on the Scientific Advisory Panel of the Melanoma Research Foundation and serves on the External Advisory Panel for the Purdue University Institute for Drug Discovery. In addition, he sits on the Translation Research Council for CureSMA and is co-founder and Chief Scientific Office of a non-profit organization, Spinal Muscular Atrophy Research Team (SMART). He obtained his undergraduate degree from the University of Notre Dame, received his Ph.D. in pharmaceutical sciences from Wayne State University and completed postdoctoral training in toxicology and cellular/molecular immunology at the National Institutes of Health under the mentorship of Dr. Lance Pohl. Tim was also previously a long-standing board-certified Diplomat of the American Board of Toxicology.

paul thibodeau
Paul Thibodeau, PhD
Chief Business Officer

Dr. Paul Thibodeau has nearly 20 years of business development experience in the biopharmaceutical industry and a proven track record in transaction execution.

Dr. Thibodeau joins HotSpot from Novartis (NYSE: NVS), where he held numerous business development positions, most recently leading M&A transactions across all of Novartis’ therapeutic areas, where he was responsible for deal sourcing, evaluation, and execution of acquisitions and divestments. Prior to joining Novartis in 2016, he served as Senior Director of Global Business Development at Teva Cephalon, heading up all out-licensing and discovery deals for its specialty pipeline. Previously, he held numerous business development positions with increasing responsibilities at Sanofi Genzyme across its oncology, transplant and multiple sclerosis franchises. Dr. Thibodeau was a Postdoctoral Research Fellow at the Institut national scientifique et de la recherche médicale (INSERM) in Paris, France.

Dr. Thibodeau received his Ph.D. in Cell Biology and Radiobiology from the Université de Sherbrooke in Quebec, Canada, and his B.S. in Biology and Biochemistry from the Université de Moncton in New Brunswick, Canada. He also completed an MBA at the MIT Sloan School of Management.

Board of
Directors

fouad azzam
Fouad Azzam, PhD
Director
Biography
Bruce Booth
Bruce Booth, PhD
Chairman
Biography
jose pepe carmona
Jose “Pepe” Carmona
Director
Biography
jill carroll
Jill Carroll
Director
Biography
ash khanna
Ash Khanna, PhD
Director
Biography
Jonathan Montagu
Jonathan Montagu
Co-Founder and Chief Executive Officer
Biography
daniel omstead
Daniel Omstead, PhD
Director
Biography
victoria richon
Victoria Richon, PhD
Director
Biography
graziano seghezzi
Graziano Seghezzi
Director
Biography
fouad azzam
Fouad Azzam, PhD
Director

Fouad Azzam, PhD, MBA, joined LSP in 2007. He became a Partner of the firm in that same year. Fouad’s prime focus and responsibility within LSP is to invest in unlisted securities and manage the firm’s North American operations. Prior to joining LSP, Fouad was the Managing Director of Eastman Ventures, the investment arm of Eastman Chemical Company, where he built-up its Healthcare and Advanced Materials practices. In his role as Managing Director, he was responsible for numerous early- and late-stage investments across the US & Europe. Fouad brings a wealth of investment expertise to the LSP team. Prior to his role at Eastman Ventures, Fouad held senior leadership positions at Eastman Chemical including roles in Innovation, Corporate Strategy, Corporate Development (M&A) and New Business Development. His career also includes business, operating, and technology roles at Occidental Chemical and BFGoodrich.

Among others, Fouad is currently a Director at NKarta Therapeutics (NASDAQ: NKTX), Xylocor Therapeutics, Endotronix, and Cardiac Dimensions. Fouad’s academic credentials include a Master’s degree and PhD in Chemical Engineering from the University of Akron in Ohio. In addition, Fouad obtained an MBA in Finance & Strategy from the University at Buffalo in New York. Fouad lives in the greater Boston area with his wife and two children.

Bruce Booth
Bruce Booth, PhD
Chairman

Bruce Booth is Chairman of HotSpot’s board of directors and a partner at Atlas Venture.  He focuses on novel biopharmaceutical products, therapeutic platforms, and innovative biomedical technologies.

Bruce is currently chairman of AvroBio (NASDAQ: AVRO), Kymera Therapeutics, Unum Therapeutics (NASDAQ: UMRX), HotSpot Therapeutics, miRagen Therapeutics (NASDAQ: MGEN), Nimbus Therapeutics, and Rodin Therapeutics, and also serves on the boards of Lysosomal Therapeutics, Magenta Therapeutics (NASDAQ: MGTA), Unum Therapeutics (NASDAQ: UMRX). He previously served on the boards of past Atlas companies Avila (acquired by Celgene), Padlock (acquired by BMS), Prestwick (acquired by Biovail), Stromedix (acquired by Biogen), and a number of other ventures.

Bruce serves as an advisor in various capacities to UCB, Shire, Pfizer, Takeda, and the Gates Foundation. He also serves on the board of the National Venture Capital Association.

Bruce blogs about biotech and venture capital topics at LifeSciVC.com, which is syndicated on Forbes. He has published numerous scientific papers and has authored various biotech venture capital review articles, including several in Nature Biotechnology.

Prior to joining Atlas in 2005, Bruce was a consultant at McKinsey & Company, as well as an investor for Caxton Health Holdings. As a British Marshall Scholar, Bruce received a D.Phil. (PhD) in molecular immunology from Oxford University. His work focused on the study of HIV and tumor immune responses. He received a BS in biochemistry, summa cum laude, from The Pennsylvania State University.

jose pepe carmona
Jose “Pepe” Carmona
Director

Mr. Carmona currently serves as Chief Financial Officer of ADC Therapeutics, Inc. (NYSE: ADCT), a commercial-stage biotechnology company helping to improve the lives of those affected by cancer with its next-generation, targeted antibody drug conjugates, where he is responsible for all the financial aspects of the business, as well as business development, information technology and procurement. Prior to joining ADC in December 2022, Mr. Carmona served as Chief Financial Officer of Rubius Therapeutics (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is biologically engineering red blood cells to create a new class of cellular medicines for the treatment of cancer and autoimmune diseases. Mr. Carmona previously served as the Chief Financial Officer of Radius Health (Nasdaq: RDUS), a biopharmaceutical company developing and commercializing endocrine therapeutics. Prior to joining Radius, he was Chief Financial Officer of Innocoll Holdings PLC, acquired by Gurnet Point L.P. Previously, he held numerous financial management positions with increasing responsibilities at Novartis AG (NYSE: NVS), in various divisions, as Chief Financial Officer in Europe, North America, Latin America and held other senior global financial roles. Mr. Carmona currently serves on the Board of Directors of Senda Biosciences.

Mr. Carmona received his B.S. in Industrial Civil Engineering from Universidad Tecnica Federico Santa Maria in Valparaiso, Chile, and his M.B.A. from Columbia Business School in New York City.

jill carroll
Jill Carroll
Director

Jill Carroll is a Partner at SR One. Prior to joining SR One in 2011, Jill was a Senior Director of Strategic Planning and Corporate Development at Dynavax Technologies, where she was involved in multiple pharma partnering deals as well as substantial private and public financings. She previously was a health care at Clearview Projects and Mercer Management Consulting. Jill earned a BS in chemistry from Duke University and an MS in biochemistry from Johns Hopkins University.

ash khanna
Ash Khanna, PhD
Director

Dr. Ash Khanna is a Venture Partner at Pivotal bioVenture Partners and brings significant experience in the venture capital, pharmaceutical and biotech arena. Most recently, he co-founded Vaxcyte (NASDAQ: PCVX), a Pivotal bioVenture Partners portfolio company, where he served as chief business officer. He also serves or has served on the Boards of Fountain Therapeutics, Evommune Inc and Vaxcyte. Previously he was president and chief business officer of Imagen Biotech, a VC-backed startup developing treatments for severe ophthalmic diseases. Prior to his operating roles, Dr. Khanna was a principal at SV Life Sciences (SVLS), a healthcare focused venture capital firm, where he led and managed investments in many biotech and diagnostic companies including, among others, Ophthotech, Sutro BioPharma, Mpex Pharmaceuticals, Good Start Genetics and Itero Biopharma.
He started his career in the pharmaceutical industry at Bristol-Myers Squibb where he held various positions including Team Leader responsible for the clinical advancement of multiple diabetes programs including the currently marketed products, Onglyza® (Dipeptidyl peptidase-4 inhibitor) and Farxiga® (SGLT2 inhibitor). Dr. Khanna is a co-inventor on the Onglyza® patent. Dr. Khanna holds a Ph.D. in Pharmaceutics from the State University of New York at Buffalo, an M.B.A. in Finance from The Wharton School, and a B.S. in Pharmacy from the University of Bombay.

Jonathan Montagu
Jonathan Montagu
Co-Founder and Chief Executive Officer

A trained chemist, biotech entrepreneur and specialist in startup operations and business development, Jonathan’s unique perspective aligns business and science interests. Inspired by the ability to translate lab-bench innovation into meaningful therapies for patients, Jonathan is driven to lead HotSpot to solve problems that the industry has grappled with for decades.

Prior to co-founding HotSpot, Jonathan served as Chief Business Officer at Nimbus Therapeutics, where he helped establish the company’s drug discovery platform and pipeline. He also served as Vice President, Business Development at Concert Pharmaceuticals (CNCE), and was instrumental in securing a $1B multi-product transaction for the company with GSK. Jonathan serves as a Non-Executive Director at OMass Therapeutics and is currently an Advisor at Atlas Venture.

Jonathan trained as a chemist at Oxford University, Cold Spring Harbor Laboratory, The Scripps Research Institute, and Cancer Research UK.  Jonathan received an MBA from Stanford Graduate School of Business.

daniel omstead
Daniel Omstead, PhD
Director

Dr. Omstead is the Head of Healthcare Investments at abrdn, Inc. (formerly Tekla Capital Management LLC). Prior to joining Tekla, Dr. Omstead was President and CEO of Reprogenesis, Inc., a private development stage biotech company which developed therapies in the field of tissue engineering and regenerative medicine. Before joining  Reprogenesis, Dr. Omstead was Senior Vice President, Research and Development, at Cytotherapeutics, Inc, a public biotech company. Prior to entering the biotech industry, Dr. Omstead was employed for fourteen years in positions of increasing responsibility within the pharmaceutical industry at Ortho Pharmaceutical Corporation and at the R.W. Johnson Pharmaceutical Research Institute, both divisions of Johnson & Johnson, and at Merck, Sharp and Dohme Research Laboratories, a division of Merck & Co., Inc. Dr. Omstead provides each Fund with insights into both pharmaceutical and biotech companies. Dr. Omstead holds PhD and Master’s Degrees in Chemical Engineering and Applied Chemistry from Columbia University and a BS degree in Civil Engineering from Lehigh University. He is an emeritus member of the Board of Directors of a non-profit agency that provides emergency shelter, housing and supportive services to homeless and low-income individuals and families in the Boston area. Dr. Omstead was also a member of the Board of Trustees at the Joslin Diabetes Center.

victoria richon
Victoria Richon, PhD
Director

Dr. Richon is a scientifically trained executive with decades of leadership experience in small biotechnology companies, global pharmaceutical companies and academia.  Before joining Ribon, Dr. Richon was the Vice President and Global Head of Oncology Research and Translational Medicine at Sanofi where she led the company’s early oncology efforts.  Prior to Sanofi, Dr. Richon was Vice President of Biological Sciences at Epizyme, Inc., a biotechnology company pioneering therapeutics based upon epigenetics.  Earlier in her career, she was Founder and Executive Director of Aton Pharmaceuticals which was acquired by Merck in 2004.  Aton was formed to develop HDAC inhibitors, including vorinostat, an HDAC inhibitor that Dr. Richon developed during her tenure at Sloan-Kettering Cancer Center and vorinostat was the first HDAC inhibitor approved by the FDA while she was at Merck.

Dr. Richon received her PhD in Biochemistry at the University of Nebraska Medical Center and a BA in Chemistry at the University of Vermont.

graziano seghezzi
Graziano Seghezzi
Director

Graziano Seghezzi is managing partner at Sofinnova Partners, which he joined in 2006 and where he is an active member of the investment team for the Sofinnova Capital Funds.

Graziano serves on the Board of Directors of several companies he helped create and finance, including GlycoEra, Enthera, Erydel, Inotrem, Mission Therapeutics, and Crescendo Biologics. He is responsible for a number of substantial exits, including Corvidia Therapeutics, which was sold to Novo Nordisk for €2.1 billion in 2020; Hookipa Pharma, floated on the Nasdaq in 2019; GlycoVaxyn, sold to GlaxoSmithKline in 2015, and Omthera Pharmaceuticals, which went public on the Nasdaq in 2013 and was then sold to AstraZeneca the same year.

He has also been the main driver behind Sofinnova Partners’ growing presence in his native Italy, establishing the country’s first biotech accelerator, BiovelocITA, in 2015, and the Sofinnova Telethon Fund in 2018.

He started his career in venture capital in 2001 at Sofinnova Partners and was at Index Ventures from 2003 to 2006. Prior to that, Graziano spent five years working in academic research at New York University’s School of Medicine, studying oncology and cardiovascular diseases. Graziano holds a degree in genetics and microbiology from the University of Pavia, Italy, and an MBA from RSM-Erasmus University, The Netherlands.

Clinical
Advisors

Jason Luke, MD, FACP
University of Pittsburgh (UPMC) Hillman Cancer Center
Background
Aurelien Marabelle, MD, PhD
Institute Gustave Roussy (France)
Background
Ignacio ’Nacho’ Melero, MD, PhD
University of Navarro (Spain)
Background
Robert Clark, MD
University of Connecticut Health Center
Background
Greg Beatty, MD, PhD
University of Pennsylvania
Background
Rachel Humphrey, MD
Independent BioPharma executive
Background

Scientific
Experts

Karen Bernstein, PhD
Chairman, BioCentury
Robert Copeland, PhD
President & CSO, Accent Therapeutics
Lenny Dang, PhD
VP, Biochemistry and Biophysics, Agios Pharmaceuticals
Dan Grau, M Phil
CEO, Avilar Therapeutics
Nicholas Keen, PhD
CSO, Bicycle Therapeutics
Kevin Koch, PhD
President & CEO of Edgewise Therapeutics
Robert Lewis, PhD
Consulting Professor, Stanford University School of Medicine
Jonathan Mason, PhD
Senior Research Fellow, Heptares Therapeutics
Iain Kilty, PhD
CSO, Sitryx
Jo Viney, PhD
Co-Founder & CSO, Pandion Therapeutics

Investors
(alphabetical order)